Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

Participants needed: 170
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Iovance Biotherapeutics, Inc.Updated: Jun 26, 2026Locations: 71
Eligibility criteria

Patients who are over 70 years of age may be allowed to enroll after discussion... [+11]

Patients who have EGFR, ALK or ROS1 driver mutations [+7]

Read more
Status: Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.

Participants needed: 670
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Iovance Biotherapeutics, Inc.Updated: Jun 26, 2026Locations: 81
Eligibility criteria

Participant has a histologically or pathologically confirmed diagnosis of Stage... [+6]

Participant has melanoma of uveal/ocular origin. [+8]

Read more
Status: Recruiting

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.

Participants needed: 42
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Iovance Biotherapeutics, Inc.Updated: Jun 15, 2026Locations: 5
Eligibility criteria

Participant must be ≥ 18 years of age at the time of signing the informed consen... [+5]

Participant has symptomatic untreated brain metastases. [+7]

Read more
Status: Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Participants needed: 53
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Iovance Biotherapeutics, Inc.Updated: Jun 11, 2026Locations: 11
Eligibility criteria

Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresect... [+12]

Participants who have melanoma of uveal/ocular origin. [+6]

Read more
Status: Available

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

The objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.

Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: Iovance Biotherapeutics, Inc.Updated: Apr 20, 2026Locations: 48
Eligibility criteria

Eligible for treatment with AMTAGVI per United States Prescribing Information (U... [+2]

History of hypersensitivity to cyclophosphamide, mesna, fludarabine, or any comp... [+5]

Read more
Status: Recruiting

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

Participants needed: 60
Trial details
Phase: Phase 2Age: 18-70Biological sex: FemaleType: InterventionalSponsor: Iovance Biotherapeutics, Inc.Updated: Oct 30, 2025Locations: 12
Eligibility criteria

Participants must have a histologically confirmed diagnosis of endometrial carci... [+10]

Participants who have symptomatic untreated brain metastases. [+5]

Read more